Gata4 Gene Therapy for Cardiac Diastolic Function Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure with preserved ejection fraction (HFpEF) are inadequate due to the lack of effective methods to improve cardiac diastolic function, which is characterized by fibrosis, cardiac hypertrophy, and inflammation, and direct cardiac reprogramming techniques require multiple genes without a realized vector for simultaneous introduction.
Innovation Solution
A cardiac diastolic function-improving agent comprising a polynucleotide encoding a reprogramming factor polypeptide Gata4, which upregulates Gata4 gene expression in cardiac fibroblasts, potentially improving diastolic function by addressing underlying pathological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct cardiac reprogramming is performed by introducing multiple reprogramming genes (Gata4, Mef2c, Tbx5) into fibroblasts, then cardiomyocyte generation is achieved, but the complexity of the treatment increases and no effective vector has been realized for simultaneous gene introduction
Solution Approach 1:
The patent segments the complex multi-gene reprogramming process into individual single-gene interventions. Instead of simultaneously introducing multiple reprogramming genes (Gata4, Mef2c, Tbx5) as required by conventional direct cardiac reprogramming, the invention achieves cardiomyocyte differentiation by introducing only the Gata4 gene into cardiac fibroblasts, thereby simplifying the gene introduction system while maintaining therapeutic efficacy
Solution Approach 2:
The patent extracts the essential reprogramming function from the complex multi-gene system and identifies Gata4 as the key transcription factor responsible for cardiomyocyte differentiation. By isolating and utilizing only Gata4, the invention eliminates the need for concurrent introduction of Mef2c, Tbx5, and other genes, thereby reducing vector complexity and facilitating clinical translation
2Reliability
If Gata4 gene expression is upregulated in cardiac fibroblasts to improve diastolic function, then cardiac diastolic function is improved, but the underlying pathological mechanisms of HFpEF remain incompletely understood
Solution Approach 1:
The patent applies preliminary action by first upregulating Gata4 expression in cardiac fibroblasts to improve cardiac diastolic function in HFpEF models, and then subsequently investigating the downstream molecular mechanisms and pathological pathways. This approach allows therapeutic benefit to be achieved first, followed by mechanistic elucidation, thereby addressing both clinical need and scientific understanding
Data Source
Figure 1~2
Figure 3~4
Figure 5~7
AI summary
The cardiac diastolic function-improving agent according to an embodiment of the present invention comprises a polynucleotide encoding a reprogramming factor polypeptide Gata4.